Short Takes
Video Interviews With Industry Leaders
The Digital Health Coalition partners with a wide array of pharmaceutical industry leaders and key stakeholders to facilitate and disseminate insights on a range of topics related to digital pharmaceutical marketing innovation.
- View Interviews
Recent DHCG Disruptive Dose
Disruptive Dose Archive
- Nicholas Mills | Senior Partner, McKinsey & Company
- Randy Keim | Senior Director of HCP & Consumer Marketing, Sanofi
- Jeremy Mittler | Co-Founder and CEO, Blueprint Audiences
- Shwen Gwee | AI & Innovation Leader
- RJ Lewis | Founder & CEO, eHealthcare Solutions
- Colin Banas | Chief Medical Officer, DrFirst
- Nivi Mogali | Director, Enterprise Omnichannel Analytics, GSK
- Ray Rotolo | Co-Founder, Populus
- Dr. Osama Hashmi | Chief Product Officer, Impiricus
- Michael Rowbotham | Commercial Innovation, Pfizer
- Jane Urban | Chief Data and Analytics Officer, Improzo
- Sarah Caldwell | GM, Crossix Analytics, Veeva
- Shawna Moore | Regional Business Director, Novo Nordisk
- Ezra Suveyke | CPO/CTO, PulsePoint
- Alex Davis | Director, Brand Strategy Biosimilars, Organon
- Damon Basch | VP, Head of Digital Health Media, Veradigm
- Karen Lazan | Healthcare Consumer Marketing Expert, karenlazan&co Consultancy (Regeneron & Pfizer alum)
- Sanjeev Menon, Head of Partnerships, Ubie
- RJ Lewis, Founder & CEO, eHealthcare Solutions
- Darshan Kulkarni, Regulatory and Compliance Attorney for the Life Sciences, The Kulkarni Law Firm
- Josh Simon, SVP, Social Center of Excellence, Centered, CMI Media Group
- Andy Kennemer, CXellence Digital Advisors
- Rusty Rahmer, CX/Digital Transformation Leader
- Paul Murasko, Head of Digital Innovation & Marketing Operations, Azurity
- Dorothy Gemmell, CCO, GoodRx
- Amar Duggasani, CEO, HealthLink Dimensions
- Nandini Nayar, Global Digital Health and innovation Lead, Sanofi
- Desiree Priestley, Health Experience Officer, Otsuka Precision Health
- Shwen Gwee, #GenAI4Pharma
- Yin Ho, Health IT CEO and Entrepreneur
- Mark Gaydos, Regulatory Expert, former Sanofi
- Andrew Burns, CRO, DrFirst
- Dr. Shivag Joshi, Sermo Medical Advisory Board and Neurologist
- Chris Neuner, President Throtle
- Michael Sivak, Senior Director, Customer Experience & Enterprise Digital Capabilities AstraZeneca
- Dr Jenny YU, Chief Health Officer Healthline
- Meghan Sarli, Principal, Marketing Strategy & Client Insights PatientPoint
- Dr Ashish Rana, Medical Advisory Board Sermo
- Brandi Ascione, EVP, Managing Director, Underscore Marketing
- Jay Carter, EVP Business Development Juice Pharma
- Milet Koo, Team Lead Social Media Genentech
- Jim Delash, Multi-Channel Marketing Director GSK
- Richard Schwartz, Life Sciences Industry Practice Lead Qualtrics
- Fay McCray, Vice President & Head of Health Equity and Social Impact Healthline Media
- Fred Bennett, Chief Digital Officer, BGB Group
- Tim Panetello, CEO, Relevate Health
- Louis Naimoli, Director, Programmatic Sales and Business Development, Haylo
- Erica Taylor, VP, Chief Marketing Officer, Genentech
- Jen Alper, Senior Director, US Women’s Health Portfolio Team Lead Pfizer
- Meghan Rivera, US Managing Director Organon
- Marianne Swift, Director of Client Partnerships Spotify
- William Febbo, CEO OptimizeRx
- Nik Kolatker, Vice President, US Medical Affairs Genentech
- Kristi Veitch, Executive Vice President, Human Resources Intouch Group
- Peter Kirk, Founder Sermo
- Peter Freidman, Chairman and CEO Liveworld
- Web Sun, CEO Komodo Health
- Heidi Anderson Hupe, SVP, ASO Strategy Teladoc
- Derek Choy, Co-Founder & COO Aktana
- Richard Schwartz, Life Sciences and Medical Device Industry Cx Practice Lead Medallia
- Spencer Curtis, Head of Digital Strategy, Otsuka Pharmaceutical
- Monique Levy, Chief Commercial and Strategy Officer, Woebot Health
Senior Partner | McKinsey & Company
View LinkedIn
In this DHCG Disruptive Dose, Mark Bard speaks with Nicholas Mills, Senior Partner at McKinsey & Company, about the evolving role of AI in pharmaceutical commercial operations and what separates hype from genuine transformation. Mills shares McKinsey’s research revealing that while AI adoption is accelerating across pharma, many organizations struggle to move beyond pilots to scaled implementation that delivers measurable business impact. The conversation explores the critical importance of change management and organizational readiness, with Mills emphasizing that successful AI deployment requires more than just technology—it demands reimagining workflows, upskilling teams, and ensuring leadership commitment to transformation. Mills discusses practical applications where AI is already delivering value, from accelerating content generation to enhancing HCP targeting precision, while cautioning against pursuing AI for its own sake rather than solving specific business problems. He offers a pragmatic perspective on measuring ROI, noting that the most successful pharma AI initiatives start with clear use cases tied to business outcomes, build cross-functional buy-in early, and treat implementation as an iterative learning process rather than a one-time deployment.
Senior Director of HCP & Consumer Marketing | Sanofi
View LinkedIn
In this DHCG Disruptive Dose, Mark Bard of the DHC Group speaks with Randy Keim, Senior Director of HCP & Consumer Marketing at Sanofi, about implementing AI-powered personalization in pharmaceutical marketing. Keim shares how successful AI adoption requires organizational transformation and change management, not just new technology, emphasizing that AI should enhance rather than replace human judgment in healthcare marketing. The conversation explores how marketers can move beyond basic segmentation toward individualized experiences at scale while maintaining authenticity and compliance. Keim discusses measuring meaningful ROI through KPIs that connect AI-driven personalization to tangible outcomes, and offers candid insights on separating genuine AI transformation from hype, noting that real value comes from strategically applying AI to solve specific challenges that help healthcare professionals and patients receive relevant, timely information.
Co-Founder and CEO | Blueprint Audiences
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of The DHC Group speaks with Jeremy Mittler, a data privacy expert who recently launched Blueprint Audiences. Mittler explains how 22 state privacy laws now create greater challenges than HIPAA, particularly around inferences and model-based targeting. He outlines three privacy-safe approaches: opted-in consented data, contextual advertising, and aggregate insights. The discussion emphasizes that all stakeholders share compliance responsibility and must move beyond checklists to adopt a “privacy-first” mindset. Using Apple as an example, Mittler advocates for building privacy into the consumer experience as a competitive advantage, concluding that transparency and empathy are essential for navigating today’s complex regulatory landscape.
AI & Digital Innovation Leader
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of The DHC Group and Shwen Gwee explore AI’s transformative impact on pharmaceutical sales and marketing. Gwee identifies key applications including back-office automation, patient support programs connecting physicians, pharmacies, and payers, and ambient listening tools that reduce administrative burden—achieving adoption rates far faster than EMRs. He emphasizes treating AI initiatives like clinical trials, moving from pilot to scale through phased testing while maintaining human oversight to address bias and hallucinations. The conversation highlights a “real inflection point” as AI-powered answer engines like Google’s Gemini, Open Evidence, and Doximity’s tools become the “true front door” to medical information, finally giving physicians one place to find everything. However, this shift threatens brand websites and publishers with declining traffic as these platforms deliver answers without requiring click-throughs. Gwee concludes that pharma must reimagine content strategy to surface effectively in these new engines and reach physicians at the point of decision.
Founder & CEO | eHealthcare Solutions
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group and RJ Lewis of eHealthcare Solutions discuss AI’s disruptive impact on the medical publishing industry. Lewis notes that as search becomes an “answer engine,” it serves physicians better but poses an “existential risk” to publishers. This trend is already causing web traffic for commercial publishers to plummet by 40-50%, threatening the ad-revenue models that fund the creation of medical content and research.
Drawing parallels to the decline of the news industry, Lewis expresses concern that medical publishing could be similarly gutted. To survive, publishers must explore new models, such as charging users or LLMs for subscriptions to access unique, high-value content. The discussion highlights the possibility of new aggregators emerging, like an “Open Evidence” becoming the Spotify of medical research. They conclude that the future is uncertain and changing rapidly, but the current publishing model is facing a significant threat.
Chief Medical Officer | DrFirst
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group sits down with Dr. Colin Banas of DrFirst to discuss the intersection of technology and healthcare, with a focus on specialty care and access. Dr. Banas shares how his early experiences as a hospitalist during the rollout of major EHR systems shaped his passion for improving the provider and patient experience through technology. The conversation highlights the challenges of implementing digital tools in clinical settings, the importance of reducing friction for physicians, and the opportunities to leverage innovation to improve specialty care delivery. Together, they emphasize the need for practical, user-centered solutions that balance efficiency, usability, and better outcomes for both patients and providers.
Director, Enterprise Omnichannel Analytics Capabilities | GSK
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group speaks with Nivi Mogali, Director of Enterprise Omnichannel Analytics Capabilities at GSK, about the intersection of data, AI, and patient care. Mongali discusses how pharma companies can responsibly scale AI initiatives by balancing compliance requirements with the pursuit of meaningful patient outcomes. The conversation highlights the need to move beyond ROI and script lift as sole measures of success, emphasizing instead the importance of demonstrating how AI can directly serve patients. Together, they explore how bridging technology, analytics, and care delivery can shape a more impactful and sustainable future for the industry.
Co-Founder | Populus
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group speaks with Ray Rotolo, Co-Founder of Populus, about the vision and evolution behind the company’s founding. Rotolo shares how early conversations around telehealth and virtual care in 2019 inspired a proactive approach to digital transformation in healthcare. Framed by the idea of “skating to where the puck is going,” the discussion explores how Populus set out to bridge gaps between pharma, physicians, and patients by anticipating the needs of a digitally enabled healthcare system. The conversation highlights the role of timing, adaptability, and forward-thinking partnerships in driving sustainable innovation.
In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group speaks with Dr. Osama Hashmi, Chief Product Officer at Impiricus, about the origins and mission behind the company. Dr. Hashmi shares how his early experience as a resident at Grady Memorial Hospital inspired a vision to solve real-world care coordination challenges, especially those faced by underserved patients. The conversation explores the pain points in healthcare delivery, the role of technology in streamlining access to care, and the need to rethink how the industry supports physicians and patients. Together, they highlight the importance of empathetic design, systemic innovation, and practical solutions in transforming the healthcare landscape.
Chief Product Officer, Impiricus
View LinkedIn
Commercial Innovation, Pfizer
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group sits down Michael Rowbotham to explore the evolution of marketing from the dot com era to the current landscape shaped by AI and omnichannel strategies. They discuss lessons learned from past experiences, the importance of understanding customer behavior, and the need for effective metrics in marketing. The conversation emphasizes the significance of adapting to new technologies while maintaining core marketing principles.
Chief Data and Analytics Officer, Improzo
View LinkedIn
In this DHCG Disruptive Dose episode, Mark Bard of the DHC Group sits down with Jane Urban, Chief Data and Analytics Officer at Improzo, to discuss the critical role of data in commercial operations, the evolution of clinicians in the digital age, and the transformative potential of AI in the pharmaceutical industry. They explore the importance of understanding data, the need for operational improvements, and the strategies for adopting AI technologies. The discussion emphasizes the necessity of continuous learning and adaptation in a rapidly changing work environment, particularly in healthcare and technology sectors.
Receive exclusive interviews and articles — delivered straight to your inbox every month.